What one share of CervoMed holds
We are a clinical-stage biotechnology company developing treatments for age-related brain disorders. Our lead drug candidate, neflamapimod, is an investigational, orally administered small-molecule drug that readily crosses the blood brain barrier and selectively inhibits the enzyme p38α, a key driver of neuroinflammation and synaptic dysfunction.
CervoMed’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.03 |
|---|---|
| Profit | −$3.19 |
| Cash and investments | $1.84 |
| Book value | $1.70 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | $1.21 | −$2.02 | — | — | — | $4.50 |
| 2025 | $0.44 | −$2.98 | — | — | — | $1.97 |
Common questions about CervoMed
How much does one share of CervoMed earn?
Over the last 12 months, CervoMed lost $3.19 for each share on $0.03 of sales.
Does CervoMed pay a dividend?
CervoMed didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is CervoMed’s book value per share?
CervoMed’s book value is $1.70 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of CervoMed have?
Each share of CervoMed has $1.84 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.